Célia Gasselin

Articles by:Célia Gasselin

Célia joined LabTwin after several years of experience in international research and science communication. After pursuing a PhD in Neurosciences at the French National Institute for Health and Medical Research (INSERM), Célia joined the highly innovative Swiss institution EPFL as a neuroscientist where she performed state-of-the-art in vivo experiments. Here, she was engaged in the full digital transformation of her laboratory with the development and integration of LIMS-ELN and connected devices in her daily routine. It is with deep passion for empowering science efficiency that she joined LabTwin team in their journey to implement the Lab of the Future.

Recent Posts

Supporting Scientists in a Semi Automated (Digital lab Assistants)

Supporting Scientists in a Semi Automated (Digital lab Assistants)

Pharmaceutical companies face increasing pricing pressure on new medicines, and many have turned to automation to shorten product development timelines, facilitate compliance and reduce costs. By automating repetitive manual tasks, such as..

Why an ELN Needs a Helping Hand

Why an ELN Needs a Helping Hand

We are in the Age of Information. The recent exponential increase in computational power now enables data-driven decisions across organizations, streamlining workflows and improving efficiency. Therefore, many companies are searching for the best..

Documenting in vivo Preclinical Studies 2022

Documenting in vivo Preclinical Studies 2022

In preclinical drug development, in vivo studies are a mandatory step in the process of turning lead compounds into drug candidates. Regulatory agencies require in vivo safety and efficacy data from animal models before approving novel candidates..

Microbiological Testing in cGMP-environment with LIMS and MES software

Microbiological Testing in cGMP-environment with LIMS and MES software

We all expect that the medicine we receive is safe and effective. For pharmaceutical products to meet these requirements, regulatory authorities, such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA), ensure..

Cell-based Assay for High-content Screening in Pharma

Cell-based Assay for High-content Screening in Pharma

Drug discovery and development lead to new treatments for diseases. However, it is a costly, time-consuming and challenging process—developing a marketable drug can take more than 10 years and cost around a billion dollars. One of the reasons for..

Voice-powered Method-dev for Protein Expression in Lab of the Future

Voice-powered Method-dev for Protein Expression in Lab of the Future

When the human genome was sequenced in 2003, it became possible to identify the gene and protein changes that occur in various diseases, such as cancer. Ever since, the field of proteomics has been booming to respond to the ever-increasing..

book now